Synapse - Thoracic Oncology

Results (337)

High-dose osimertinib for CNS progression in EGFRþ NSCLC: A multi-institutional experience

Journal Article

Piper-Vallillo, A. J.; Rotow, J. K.; Aredo, J. V.; Shaverdashvili, K.; Luo, J.; Carlisle, J. W.; Husain, H.; Muzikansky, A.; Heist, R. S.; Rangachari, D.; more...
JTO Clinical and Research Reports (2022)

Fulltext@MSK | Save

SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors

Journal Article

Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase

Journal Article

Boucai, L.; Salas-Lucia, F.; Krishnamoorthy, G. P.; Sherman, E.; Rudin, C. M.; Drilon, A.; Bianco, A. C.; Fagin, J. A.
JCO Precision Oncology (2022)

Fulltext@MSK | Save

Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK/ROS1/RET-rearranged lung cancers

Journal Article

Hubbeling, H.; Choudhury, N.; Flynn, J.; Zhang, Z. G.; Falcon, C.; Rusch, V. W.; Park, B. J.; Ziv, E.; Shaverdian, N.; Gelblum, D. Y.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: Safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

Meeting Abstract

Foy, S.; Jacoby, K.; Bota, D.; Hunter, T.; Schoenfeld, A.; Pan, Z.; Stawiski, E.; Ma, Y.; Lu, W.; Peng, S. M.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumorimmune microenvironment

Meeting Abstract

Maxey, J.; Thompson, M.; Campbell, K.; Kamphaus, B.; Bustami, Z.; Santulli-Marotto, S.; Wells, D.; Boffo, S.; Salvador, L.; Scumpia, P.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer

Meeting Abstract

Nguyen, E.; Chow, A.; Rudin, C.; Sen, T.; Taniguchi, H.
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 anti-vista antibody in patients with advanced solid tumors

Meeting Abstract

Noelle, R.; Johnson, M.; Rodon, J.; Zauderer, M.; Lewis, L.; Severgnini, M.; Parker, J.; Lane, M.; von Roemeling, R.; Martin, A.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

Meeting Abstract

Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

KEYNOTE-495/KeyImPaCT: Updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer

Meeting Abstract

Herbst, R.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J.; Lee, J. S.; Yang, N. C. H.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save